Proinflammatory cytokines in breast cancer: Mechanisms of action and potential targets for therapeutics

Jodi E. Goldberg, Kathryn L. Schwertfeger

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

Inflammation within the tumor microenvironment correlates with increased invasiveness and poor prognosis in many types of cancer, including breast cancer. The cytokines interleukin-6 (IL-6), tumor necrosis factor alpha (TNFα) and interleukin-1 beta (IL-1β) are critical mediators of the inflammatory response. Numerous studies have also linked these cytokines to breast cancer progression. As a result, the mechanisms by which these cytokines promote breast cancer have been recently explored using both in vitro and in vivo models. The results from these studies have led to speculation regarding the possible usefulness of targeting these cytokines in breast cancer patients. This review summarizes the most recent studies pertaining to the mechanisms by which proinflammatory cytokines promote breast cancer. Furthermore, the possibilities of targeting these inflammatory mediators in breast cancer patients using inhibitors that are currently being used in the clinic for other inflammatory conditions are discussed. Understanding both the mechanisms by which inflammatory mediators promote breast cancer and the effectiveness of anti-inflammatory drugs in treating breast cancer will lead to novel therapeutic regimens to treat this devastating disease.

Original languageEnglish (US)
Pages (from-to)1133-1146
Number of pages14
JournalCurrent Drug Targets
Volume11
Issue number9
DOIs
StatePublished - Dec 1 2010

Fingerprint

Action Potentials
Breast Neoplasms
Cytokines
Therapeutics
Interleukin-1beta
Tumors
Interleukin-6
Anti-Inflammatory Agents
Tumor Necrosis Factor-alpha
Tumor Microenvironment
Pharmaceutical Preparations
Inflammation

Keywords

  • Breast cancer
  • Cytokine
  • Inflammation
  • Interleukin-1beta
  • Interleukin-6
  • Tumor necrosis factor-alpha

Cite this

Proinflammatory cytokines in breast cancer : Mechanisms of action and potential targets for therapeutics. / Goldberg, Jodi E.; Schwertfeger, Kathryn L.

In: Current Drug Targets, Vol. 11, No. 9, 01.12.2010, p. 1133-1146.

Research output: Contribution to journalArticle

@article{4cc6d1046a9c4130ad14447d115f044c,
title = "Proinflammatory cytokines in breast cancer: Mechanisms of action and potential targets for therapeutics",
abstract = "Inflammation within the tumor microenvironment correlates with increased invasiveness and poor prognosis in many types of cancer, including breast cancer. The cytokines interleukin-6 (IL-6), tumor necrosis factor alpha (TNFα) and interleukin-1 beta (IL-1β) are critical mediators of the inflammatory response. Numerous studies have also linked these cytokines to breast cancer progression. As a result, the mechanisms by which these cytokines promote breast cancer have been recently explored using both in vitro and in vivo models. The results from these studies have led to speculation regarding the possible usefulness of targeting these cytokines in breast cancer patients. This review summarizes the most recent studies pertaining to the mechanisms by which proinflammatory cytokines promote breast cancer. Furthermore, the possibilities of targeting these inflammatory mediators in breast cancer patients using inhibitors that are currently being used in the clinic for other inflammatory conditions are discussed. Understanding both the mechanisms by which inflammatory mediators promote breast cancer and the effectiveness of anti-inflammatory drugs in treating breast cancer will lead to novel therapeutic regimens to treat this devastating disease.",
keywords = "Breast cancer, Cytokine, Inflammation, Interleukin-1beta, Interleukin-6, Tumor necrosis factor-alpha",
author = "Goldberg, {Jodi E.} and Schwertfeger, {Kathryn L.}",
year = "2010",
month = "12",
day = "1",
doi = "10.2174/138945010792006799",
language = "English (US)",
volume = "11",
pages = "1133--1146",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "9",

}

TY - JOUR

T1 - Proinflammatory cytokines in breast cancer

T2 - Mechanisms of action and potential targets for therapeutics

AU - Goldberg, Jodi E.

AU - Schwertfeger, Kathryn L.

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Inflammation within the tumor microenvironment correlates with increased invasiveness and poor prognosis in many types of cancer, including breast cancer. The cytokines interleukin-6 (IL-6), tumor necrosis factor alpha (TNFα) and interleukin-1 beta (IL-1β) are critical mediators of the inflammatory response. Numerous studies have also linked these cytokines to breast cancer progression. As a result, the mechanisms by which these cytokines promote breast cancer have been recently explored using both in vitro and in vivo models. The results from these studies have led to speculation regarding the possible usefulness of targeting these cytokines in breast cancer patients. This review summarizes the most recent studies pertaining to the mechanisms by which proinflammatory cytokines promote breast cancer. Furthermore, the possibilities of targeting these inflammatory mediators in breast cancer patients using inhibitors that are currently being used in the clinic for other inflammatory conditions are discussed. Understanding both the mechanisms by which inflammatory mediators promote breast cancer and the effectiveness of anti-inflammatory drugs in treating breast cancer will lead to novel therapeutic regimens to treat this devastating disease.

AB - Inflammation within the tumor microenvironment correlates with increased invasiveness and poor prognosis in many types of cancer, including breast cancer. The cytokines interleukin-6 (IL-6), tumor necrosis factor alpha (TNFα) and interleukin-1 beta (IL-1β) are critical mediators of the inflammatory response. Numerous studies have also linked these cytokines to breast cancer progression. As a result, the mechanisms by which these cytokines promote breast cancer have been recently explored using both in vitro and in vivo models. The results from these studies have led to speculation regarding the possible usefulness of targeting these cytokines in breast cancer patients. This review summarizes the most recent studies pertaining to the mechanisms by which proinflammatory cytokines promote breast cancer. Furthermore, the possibilities of targeting these inflammatory mediators in breast cancer patients using inhibitors that are currently being used in the clinic for other inflammatory conditions are discussed. Understanding both the mechanisms by which inflammatory mediators promote breast cancer and the effectiveness of anti-inflammatory drugs in treating breast cancer will lead to novel therapeutic regimens to treat this devastating disease.

KW - Breast cancer

KW - Cytokine

KW - Inflammation

KW - Interleukin-1beta

KW - Interleukin-6

KW - Tumor necrosis factor-alpha

UR - http://www.scopus.com/inward/record.url?scp=78651276266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651276266&partnerID=8YFLogxK

U2 - 10.2174/138945010792006799

DO - 10.2174/138945010792006799

M3 - Article

C2 - 20545607

AN - SCOPUS:78651276266

VL - 11

SP - 1133

EP - 1146

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 9

ER -